Advertisement

Guidelines and Current Recommendations in Atrial Fibrillation

  • Antoni Martínez-RubioEmail author
  • Gheorghe-Andrei Dan
Chapter
Part of the Current Cardiovascular Therapy book series (CCT)

Abstract

Atrial fibrillation (AF) is a very common arrhythmia characterized by chaotic electrical atrium activation reflected in the electrocardiogram by variable R-R intervals and absence of P waves.

Keywords

Atrial Fibrillation Catheter Ablation Structural Heart Disease Left Atrial Appendage Lone Atrial Fibrillation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Camm AJ, Lip GYH, DeCaterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P. 2012 focused update of the ESC guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33:2719–47.PubMedCrossRefGoogle Scholar
  2. 2.
    Lip GY. Stroke in atrial fibrillation: epidemiology and thromboprophylaxis. J Thromb Haemost. 2011;9 Suppl 1:344–51.PubMedCrossRefGoogle Scholar
  3. 3.
    Olesen JB, Lip GY, Hansen ML, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen AM, Gislason GH, Torp-Pedersen C. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124.PubMedCrossRefGoogle Scholar
  4. 4.
    Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182,678 patients with atrial fibrillation: the Swedish atrial fibrillation cohort study. Eur Heart J. 2012;33:1500–10.PubMedCrossRefGoogle Scholar
  5. 5.
    Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.PubMedCrossRefGoogle Scholar
  6. 6.
    Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.PubMedCrossRefGoogle Scholar
  7. 7.
    Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.PubMedCrossRefGoogle Scholar
  8. 8.
    Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P. European heart rhythm association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15:625–51.PubMedCrossRefGoogle Scholar
  9. 9.
    Lakkireddy D, Reddy YM, Di Biase L, Vanga SR, Santangeli P, Swarup V, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol. 2012;59:1168–74.PubMedCrossRefGoogle Scholar
  10. 10.
    Kaseno K, Naito S, Nakamura K, Sakamoto T, Sasaki T, Tsukada N, et al. Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation. Circ J. 2012;76:2337–42.PubMedCrossRefGoogle Scholar
  11. 11.
    Snipelisky D, Kauffman C, Prussak K, Johns G, Venkatachalam K, Kusumoto F. A comparison of bleeding complications post-ablation between warfarin and dabigatran. J Interv Card Electrophysiol. 2012;35:29–33.PubMedCrossRefGoogle Scholar
  12. 12.
    Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA. The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2012;23:264–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Kim JS, She F, Jongnarangsin K, Chugh A, Latchamsetty R, Ghanbari H, et al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm. 2013;10(4):483–9. doi: 10.1016/j.hrthm.2012.12.011.PubMedCrossRefGoogle Scholar
  14. 14.
    Lewalter T, Ibrahim R, Albers R, Camm AJ. An update and current expert opinions on percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation. Europace. 2013;15:652–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum A ́, Blomstro ̈MP, Borggrefe M, Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Davy JM, Delacre ́taz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, Granger CB, Heidbu ̈chel H, Kautzner J, Kim JS, Lanas F, Lewis BS, Merino JL, Morillo C, Murin J, Narasimhan C, Paolasso E, Parkhomenko A, Peters NS, Sim KH, Stiles MK, Tanomsup S, Toivonen L, Tomcsa ́nyi J, Torp-Pedersen C, Tse HF, Vardas P, Vinereanu D, Xavier D, Zhu J, Zhu JR, Baret-Cormel L, Weinling E, Staiger C, Yusuf S, Chrolavicius S, Afzal R, Hohnloser SH; PALLAS Investigators. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011;365:2268–76.Google Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  1. 1.Department of CardiologyUniversity Hospital of SabadellSabadell, BarcelonaSpain
  2. 2.Internal Medicine Clinic and Department of CardiologyColentina University HospitalBucharestRomania
  3. 3.Department of Internal Medicine and Cardiology, Faculty of MedicineUniversity of Medicine and Pharmacy Carol DavilaBucharestRomania

Personalised recommendations